MedTrace Logo

Diagnosis of Pancreatic Cancer by Purine Metabolite (Hypoxanthine, Xanthine) in Urine

NCT06291779 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 120

Last updated 2024-03-04

No results posted yet for this study

Summary

* This study aim to develope a diagnostic method of pancreatic cancer by using a reagent for analyzing purine metabolite (Hypoxanthine, Xanthine) in urine.
* It is safe and cost effective compare to radiologic or blood test. It can be used for initial screening test for healty population.

Conditions

  • Pancreas Cancer
  • Diagnosis

Interventions

DEVICE

Purine metabolite (Hypoxanthine, Xanthine) in urine by CubeBio

* Collect urine from the patient to measure urinary hypoxia, xanthine concentration. * Hypoxic acid, xanthine analysis in urine using High Performance Liquid Chromatography (HPLC). * After that, hypoxanthine and xanthine will be analyzed using purine metabolite analysis reagents. * Compare the cutoff of the metabolic value of Pancreas cancer clarified in the existing research and the value of the sample.

Sponsors & Collaborators

  • Seoul National University Bundang Hospital

    collaborator OTHER

  • Ho-Seong Han

    lead OTHER

Principal Investigators

  • Ho-Seong Han, M.D. Ph.D. · Seoul National University Bundang Hospital

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2022-11-30
Primary Completion
2024-02-26
Completion
2024-05-31

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06291779 on ClinicalTrials.gov